A consortium set up to respond to the outbreak, including CEPI, Gavi, the World Health Organization (WHO) and Ugandan public health authorities, have outlined a range of measures.
They include the ring vaccination trial that will deploy candidate vaccines, including the University of Oxford’s ChAdOx1 biEBOV jab, against Sudan ebolavirus which is causing an ongoing outbreak in Uganda. The aim of the trial is to minimise hospitalisations and deaths. There are currently no licensed vaccines against Sudan ebolavirus.
Oxford’s vaccine has been designed to generate an immune response against two species, Ebola virus and Sudan ebolavirus, and is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca COVID-19 vaccine.